Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Fineline Cube Dec 10, 2025
Company Deals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Fineline Cube Dec 10, 2025
Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025
Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Fineline Cube Dec 11, 2025
Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Fineline Cube Dec 10, 2025
Company Drug

GenSci’s GenSci142 Wins NMPA Nod for Bacterial Vaginosis Clinical Trials

Fineline Cube Nov 29, 2025

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary GenSci...

Company Drug

Jiuzhou Pharmaceutical Wins Tentative FDA Approval for Generic Janumet XR

Fineline Cube Nov 28, 2025

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (SHA: 603456) announced that its Abbreviated New Drug Application (ANDA)...

Company Drug

Hengrui’s Ivarmacitinib Wins NMPA Nod for Vitiligo Clinical Trials

Fineline Cube Nov 28, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that Ivarmacitinib Tablets and SHR0302...

Company Drug

Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise

Fineline Cube Nov 28, 2025

Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China’s first self‑developed CD19‑targeting CAR‑T...

Company Drug

Innovent’s Picankibart Wins NMPA Approval for Psoriasis as IL-23p19 Inhibitor

Fineline Cube Nov 28, 2025

Innovent Biologics, Inc. (HKG: 1801) announced that Picankibart Monoclonal Antibody Injection (IBI112), branded XINMEIYUE, received...

Company Deals

Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation

Fineline Cube Nov 28, 2025

Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB...

Company Drug

Boan Biotech’s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases

Fineline Cube Nov 27, 2025

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self‑developed Aflibercept Intravitreal Injection (Boyoujing)...

Company Deals

Sprint-Bioscience Sells TREX1 Program to Gilead for $14M Upfront

Fineline Cube Nov 27, 2025

Sprint Bioscience AB announced the sale of its TREX1 cancer program to Gilead Sciences, Inc....

Company Drug

Novo Nordisk’s Semaglutide 7.2 mg sNDA Submitted for Weight Management

Fineline Cube Nov 27, 2025

Novo Nordisk A/S (NYSE: NVO) announced the submission of a supplemental New Drug Application (sNDA)...

Company Drug

CSPC’s JMT206 Wins NMPA Nod for ActRII-Targeted Weight Management

Fineline Cube Nov 27, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed recombinant fully human anti‑ActRIIA/IIB monoclonal...

Company Medical Device

MicroTech’s LinX CGM Wins India Approval, Expanding Asia Diabetes Monitoring

Fineline Cube Nov 27, 2025

MicroTech Medical (Hangzhou) Co., Ltd. (HKG: 2235) announced that its LinX Continuous Glucose Monitoring (CGM)...

Medical Device

Bio-heart’s IberiRDN Wins New Zealand Nod as Only Dual-Approach Renal Denervation System

Fineline Cube Nov 27, 2025

Shanghai Bio-heart Biological Technology Co., Ltd. (HKG: 2185) announced that its Iberis Multi-Electrode Renal Denervation...

Company Drug

IASO-Bio’s Fucaso Wins Hong-Kong Approval as First China CAR-T

Fineline Cube Nov 27, 2025

IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA‑targeted CAR‑T cell...

Company Drug

BeOne’s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma

Fineline Cube Nov 27, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. FDA has accepted its...

Company Deals

Patronus Biotech Gates Foundation Grant Accelerates Malaria Vaccine Development

Fineline Cube Nov 27, 2025

Patronus Biotech Pte. Ltd. announced it has received a grant from the Gates Foundation to...

Company Deals

Innova Therapeutics Acquires Enci Therapeutics’ IVT-8086 Cancer Program

Fineline Cube Nov 27, 2025

Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT‑8086,...

Company Drug

Gene Key’s iNKT Cell Therapy Wins NMPA Nod for ARDS, First Allogeneic Ready-to-Use

Fineline Cube Nov 27, 2025

Beijing Gene Key Life Technology Co., Ltd. announced that its GKL‑006RTU Injection, China’s first novel...

Company Drug

SciClone’s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect

Fineline Cube Nov 27, 2025

SciClone Pharmaceuticals Inc. announced that Meropenem/Vaborbactam for Injection has been approved under the “Hong Kong-Macau...

Company Drug

Novartis’ Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria

Fineline Cube Nov 26, 2025

Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval...

Policy / Regulatory

CMS IRA Drug-Pricing Round 2 Delivers 62% Average Cut, Ozempic Falls 71%

Fineline Cube Nov 26, 2025

The U.S. Centers for Medicare & Medicaid Services (CMS) announced results of the second round...

Posts pagination

1 … 4 5 6 … 596

Recent updates

  • Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing
  • D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
  • Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
  • Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer
  • Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.